Pitcairn Co. Acquires 265 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Pitcairn Co. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,845 shares of the biopharmaceutical company’s stock after acquiring an additional 265 shares during the quarter. Pitcairn Co.’s holdings in Gilead Sciences were worth $632,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the 4th quarter worth $31,000. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 4.6 %

GILD opened at $107.25 on Friday. The firm has a market capitalization of $133.54 billion, a P/E ratio of 289.86, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a fifty day moving average price of $107.30 and a 200-day moving average price of $95.80. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. Gilead Sciences’s payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Royal Bank of Canada boosted their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Oppenheimer boosted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Bank of America upped their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Finally, DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.